Skip to main content

Table 2 Population demographics including unique patient LAI switch events; stratified by gender, and age. Reported as total number of events (n) and percentage (%)

From: Long-acting injectable antipsychotic (LAI) prescribing trends during COVID-19 restrictions in Canada: a retrospective observational study

One-Month Paliperidone Palmitate (PP1) to Three-Month Paliperidone Palmitate (PP3) Switches

January 2019 to December 2020

Number of Unique Patients, by Epoch

Characteristic

All PP1 to PP3 Switches

(n = 2770)

COVID Awareness Period

(n = 308)

Primary COVID Escalation Period

(n = 420)

COVID Maintenance Period

(n = 265)

Second COVID Escalation Period

(n = 301)

Pre-COVID Comparator Period

(n = 442)

Gender

 Women, n (%)

822 (29.7)

86 (27.9)

119 (28.3)

80 (30.2)

87 (28.9)

149 (33.7)

 Men, n (%)

1948 (70.3)

222 (72.1)

301 (71.7)

185 (69.8)

214 (71.1)

293 (66.3)

Age In Years

 18–35, n (%)

1002 (36.2)

102 (33.1)

150 (35.7)

113 (42.6)

129 (42.9)

149 (33.7)

 36–50, n (%)

922 (33.3)

104 (33.8)

133 (31.7)

81 (30.6)

92 (30.6)

158 (35.7)

 51–64, n (%)

604 (21.8)

79 (25.6)

86 (20.5)

50 (18.9)

59 (19.6)

102 (23.1)

 65+, n (%)

242 (8.7)

23 (7.5)

51 (12.1)

21 (7.9)

21 (7.0)

33 (7.5)

Three-Month Paliperidone Palmitate (PP3) to One-Month Paliperidone Palmitate (PP1) Switches

January 2019 to December 2020

Number of Unique Patients, by Epoch

Characteristic

All PP3 to PP1 Switches

(n = 433)

COVID Awareness Period

(n = 64)

Primary COVID Escalation Period

(n = 48)

COVID Maintenance Period

(n = 56)

Second COVID Escalation Period

(n = 59)

Pre-COVID Comparator Period

(n = 55)

Gender

 Women, n (%)

133 (30.7)

22 (34.4)

18 (37.5)

15 (26.8)

18 (30.5)

18 (32.7)

 Men, n (%)

300 (69.3)

42 (65.6)

30 (62.5)

41 (73.2)

41 (69.5)

37 (67.3)

Age In Years

 18–35, n (%)

152 (35.1)

23 (35.9)

17 (35.4)

17 (30.4)

21 (35.6)

23 (41.8)

 36–50, n (%)

151 (34.9)

22 (34.4)

21 (43.8)

17 (30.4)

18 (30.5)

17 (30.9)

 51+, n (%)

130 (30.0)

19 (29.7)

10 (20.8)

22 (39.3)

20 (33.9)

15 (27.3)

  1. The unique patient demographics are based on the earliest switch event included in this study or in an epoch. LAI, long-acting injectable antipsychotic